| Similar Articles |
|---|
 |
The Motley Fool
May 29, 2007
Brian Lawler |
The One Development-Stage Drug Stock to Own Now With such a low level of Remoxy sales baked into its share price, and minimal clinical trial risk, investors who consider Pain Therapeutics around today's share price won't be hurting in the long run, if you assume there will be a viable market for abuse-resistant opioids.   |
The Motley Fool
November 10, 2005
W.D. Crotty |
Portfolio Pain Relief Pain Therapeutics announces a significant development deal with King Pharmaceuticals. The company's stock is the largest percentage gainer on the Nasdaq -- up 48.9%. |
The Motley Fool
December 7, 2007
Brian Lawler |
Pain Continues as Planned Pain Therapeutics reports on a successful phase 3 trial for its lead drug Remoxy. |
The Motley Fool
June 27, 2011
Brian Orelli |
Double Ouch! 2 Monster Drops in 2 Trading Days Perhaps investors in Pain Therapeutics and DURECT would have rather been kept in the dark about these FDA rejections. |
The Motley Fool
November 2, 2007
Brian Lawler |
A Date With Pain Pain Therapeutics prepares for a busy fourth quarter; shares have risen 30% recently in anticipation of upcoming phase 3 data results on oxycodone compound Remoxy. Investors, take note. |
The Motley Fool
July 6, 2007
Brian Orelli |
Pain-Free Phase 2 Data Anesiva's pain medication is moving up the clinical trial ladder. The Adlea results are very promising, but investors should look at the state of the entire company before investing. |
The Motley Fool
January 6, 2012
David Williamson |
Durect Investors Feel the Pain A phase 3 failure of a lead drug crushes shares. |
The Motley Fool
April 26, 2011
Brian Orelli |
We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants. |
The Motley Fool
April 1, 2008
Brian Lawler |
A Competitive Stab at King and Pain A new, dark-horse competitor, privately held Purdue Pharma, arrives to fight King Pharma and Pain Therapeutics. |
The Motley Fool
September 17, 2010
Luke Timmerman |
Cell Therapeutics OK'd to Sell Shares to Stay Alive Is the company being straight with shareholders? |
The Motley Fool
May 2, 2007
Brian Lawler |
Another Free Quarter of Pain If the Remoxy abuse-resistant platform technology produces more positive clinical trial results later in the year, investors should have plenty to cheer about. |
The Motley Fool
March 21, 2007
Brian Lawler |
New Indication for Pain Pain Therapeutics brings a new drug into the clinic. When drug companies attempt to bring new drugs that are outside of their core competencies to market, investors always need to be wary. |
The Motley Fool
October 8, 2007
Charly Travers |
Scanning 4 Biotechs There are major events set for the following biotech companies during this quarter. Investors, take note: BioMarin Pharmaceutical... Exelixis... Neurocrine Biosciences... Pain Therapeutics... |
The Motley Fool
May 27, 2011
Brian Orelli |
What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate. |
The Motley Fool
June 11, 2008
Brian Lawler |
Pain and King Start the Countdown Who will win the race to get approval of an abuse-deterrent drug, Pain Therapeutics or King Pharmaceuticals? |
The Motley Fool
April 2, 2007
Brian Lawler |
Pain Therapeutics Pares Shares The small drugmaker announces a share buyback. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
June 22, 2011
Brian Orelli |
Building on Pfizer's Blockbuster New data for an expanded indication for Lyrica. |
The Motley Fool
March 30, 2010
Brian Orelli |
Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers. |
The Motley Fool
December 16, 2003
David Nierengarten |
Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks. |
The Motley Fool
December 29, 2011
Brian Orelli |
What to Look for From Keryx and Aeterna Zentaris in 2012 The future is uncertain for these pharmaceutical companies. |
BusinessWeek
January 17, 2005
Catherine Arnst |
No Pain, Some Gain The 50 million Americans suffering from chronic pain got a little bit of good news in December. The Food & Drug Administration greenlighted two new medications that attack pain in completely novel ways. |
The Motley Fool
January 20, 2004
David Nierengarten |
Adolor's Knocked-Out Drug The biotech's stock is pummeled after mixed-up trial results. |
The Motley Fool
May 28, 2008
Brian Lawler |
King Pays a Modest Ransom King Pharmaceuticals, a prolific acquirer of other companies' drugs, announces that it had painlessly staked its claim to yet another. |
BusinessWeek
June 14, 2004
Gene G. Marcial |
From Pain Therapeutics: A Better Pain Killer Remoxy, now in proof-of-concept trials, could become the replacement for the most popular opioid pain killer OxyContin, with a potential $1 billion market. |
The Motley Fool
December 27, 2011
Brian Orelli |
Exelixis 2011: Not What the Doctor Ordered A tale of an inability to get a Special Protocol Assessment from the FDA. |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
The Motley Fool
July 18, 2007
Brian Orelli |
Pain-Free Payday for DURECT Results from a trial take it one step closer to possible approval for a local anesthetic. Because the platform can be used with different types of drugs, DURECT could try to win additional partnerships. |
The Motley Fool
August 29, 2011
Brian Orelli |
A Less Painful FDA Decision Johnson & Johnson gains approval of Nucynta ER. |
The Motley Fool
November 22, 2006
Brian Lawler |
How to Market a Drug Too Well Cephalon's promotion of its pain drug Actiq might have crossed the line. |
The Motley Fool
June 3, 2011
Brian Orelli |
FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully. |
The Motley Fool
May 15, 2007
Mike Havrilla |
A Tale of Two Trials at YM Bio Encouraging results and ongoing drug trials give YM BioSciences' investors hope. |
The Motley Fool
August 14, 2008
Brian Lawler |
A Potentially Painless PDUFA Date King Pharmaceuticals and Pain Therapeutics get an appointment with the FDA. |
The Motley Fool
November 1, 2011
Brian Orelli |
Not Such an Excellent Outcome With the FDA Exelixis gets knocked down for not getting an SPA. |
The Motley Fool
November 5, 2007
Brian Lawler |
King's Abuse-Resistant Bet King Pharmaceuticals signs a development deal with Acura Pharmaceuticals to produce abuse-resistant painkillers. Investors, take note. |
The Motley Fool
November 5, 2010
Brian Orelli |
Better Late Than Never for Cymbalta Eli Lilly gets an expanded approval for Cymbalta. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
May 28, 2009
Robert Steyer |
Fighting an Incurable Disease United Therapeutics battles drug giants in a specialized blood-pressure treatment arena. |
The Motley Fool
December 11, 2008
Brian Orelli |
A Painful Letter from the FDA The FDA smacked down King Pharmaceuticals and Pain Therapeutics with a complete response letter for their application to market Remoxy, an abuse-resistant controlled-release form of oxycodone. |
The Motley Fool
May 17, 2007
Mike Havrilla |
Javelin Is Right on Target The company reformulates existing drugs to fill unmet needs, making its stock worthy of consideration. |
The Motley Fool
May 5, 2008
Brian Lawler |
Good News for Abuse-Resistant Drugs Drug developers working on harder-to-abuse pain remedies, including Pain Therapeutics, King Pharmaceuticals, and Alpharma, got a guarded thumbs-up from the FDA last week. |
The Motley Fool
December 23, 2011
Selena Maranjian |
3 Biotech Stocks That Had a Bad 2011 It's a volatile business, and these biotechs got the short end of the stick. |
The Motley Fool
June 6, 2011
Luke Timmerman |
Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off? |
The Motley Fool
June 21, 2011
Alexander Crawford |
Bullish Biotech: 5 Biotech Firms Making Great Strides These five biotech firms have just received great news. Should they be on your watch list? |
The Motley Fool
September 26, 2006
Brian Lawler |
A Savior for Cephalon? The FDA's approval of Fentora comes just in time for the drug company. Investors, take note. |
The Motley Fool
December 29, 2006
Brian Lawler |
No Pain for Alexza December's been good to lots of pharmas, but Alexza in particular has something to thank Santa for. Investors should pay close attention when Alexza issues its AZ-001 trial results next year. |
The Motley Fool
August 31, 2007
Brian Lawler |
4 Biotech Bets Under $10 Development stage drugmakers are among the most exciting stocks to follow. Here are four that are all worth a place on your watch list: Pharmacopeia, Pain Therapeutics, Pharmasset, and SGX Pharmaceuticals. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
